Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
$1.15
-1.4%		$1.27
$0.84
▼
$2.46
$19.00M1.53154,228 shs11,755 shs
Heatwurx Inc. stock logo
PCSA
Heatwurx
$1.90
-3.2%		$2.22
$1.67
▼
$14.24
$5.25M0.96125,201 shs8,813 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
0.00%-8.59%+2.63%-13.33%+23.69%
Heatwurx Inc. stock logo
PCSA
Heatwurx
+3.46%-9.95%-19.96%-9.53%-61.18%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
$1.15
-1.4%		$1.27
$0.84
▼
$2.46
$19.00M1.53154,228 shs11,755 shs
Heatwurx Inc. stock logo
PCSA
Heatwurx
$1.90
-3.2%		$2.22
$1.67
▼
$14.24
$5.25M0.96125,201 shs8,813 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
0.00%-8.59%+2.63%-13.33%+23.69%
Heatwurx Inc. stock logo
PCSA
Heatwurx
+3.46%-9.95%-19.96%-9.53%-61.18%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
2.25
Hold$10.00766.55% Upside
Heatwurx Inc. stock logo
PCSA
Heatwurx
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest PCSA and MRKR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/4/2026
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/21/2026
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/21/2026
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/6/2026
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/17/2026
Heatwurx Inc. stock logo
PCSA
Heatwurx
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/24/2026
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
(Data available from 9/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
$3.55M5.42N/AN/A$1.01 per share1.14
Heatwurx Inc. stock logo
PCSA
Heatwurx
N/AN/AN/AN/A$2.46 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
-$12.16M-$0.41N/AN/AN/A-343.03%-56.96%-47.82%11/12/2026 (Estimated)
Heatwurx Inc. stock logo
PCSA
Heatwurx
-$13.56M-$4.23N/AN/AN/AN/A-394.25%-244.46%10/29/2026 (Estimated)

Latest PCSA and MRKR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
-$0.25-$0.09+$0.16-$0.09$0.68 millionN/A
8/14/2026Q2 2026
Heatwurx Inc. stock logo
PCSA
Heatwurx
-$1.00-$1.19-$0.19-$1.19N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
N/AN/AN/AN/AN/A
Heatwurx Inc. stock logo
PCSA
Heatwurx
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
N/A
6.03
6.03
Heatwurx Inc. stock logo
PCSA
Heatwurx
N/A
0.87
0.87

Institutional Ownership

CompanyInstitutional Ownership
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
22.39%
Heatwurx Inc. stock logo
PCSA
Heatwurx
91.93%

Insider Ownership

CompanyInsider Ownership
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
5.70%
Heatwurx Inc. stock logo
PCSA
Heatwurx
3.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
6016.67 million15.72 millionNot Optionable
Heatwurx Inc. stock logo
PCSA
Heatwurx
202.77 million2.67 millionNot Optionable

Recent News About These Companies

Processa Pharmaceuticals to Participate in Upcoming Investor Conferences
September 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/01/3353972/0/en/processa-pharmaceuticals-to-participate-in-upcoming-investor-conferences.html
Processa Pharmaceuticals, Inc. (PCSA) M&A Call Prepared Remarks Transcript
July 29, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4927273-processa-pharmaceuticals-inc-pcsa-m-and-a-call-prepared-remarks-transcript
PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC.
July 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/29/3335130/0/en/processa-pharmaceuticals-inc-announces-acquisition-of-vidya-therapeutics-inc-and-approximately-200-million-concurrent-private-placement-to-advance-btk-inhibitor-vt-7208-in-multiple.html
Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference
January 12, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/01/12/3217020/0/en/processa-pharmaceuticals-to-attend-44th-annual-j-p-morgan-healthcare-conference.html
Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study
January 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/01/05/3212860/0/en/processa-pharmaceuticals-completes-enrollment-of-20th-patient-for-formal-interim-analysis-in-phase-2-ngc-cap-breast-cancer-study.html
PCSA Stock Soars on Upbeat Clinical Update From Breast Cancer Study
December 18, 2025  |  zacks.comhttps://www.zacks.com/stock/news/2806083/pcsa-stock-soars-on-upbeat-clinical-update-from-breast-cancer-study?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-2806083
Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer
December 17, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/12/17/3206931/0/en/processa-pharmaceuticals-provides-clinical-update-on-phase-2-study-in-metastatic-breast-cancer.html
Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025
November 5, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/11/05/3181589/0/en/processa-pharmaceuticals-announces-poster-presentation-of-adaptive-phase-2-3-pcs499-study-in-fsgs-at-asn-kidney-week-2025.html
Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies
August 7, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/08/07/3129263/0/en/processa-pharmaceuticals-secures-strategic-investment-and-evaluates-corporate-crypto-treasury-strategies.html
Processa Pharmaceuticals Provides Portfolio and Business Update
July 1, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/01/3108392/0/en/processa-pharmaceuticals-provides-portfolio-and-business-update.html
Processa Pares Gains on Equity Offer News
June 17, 2025  |  marketwatch.comhttps://www.marketwatch.com/story/processa-pares-gains-on-equity-offer-news-3b7edf2c
Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering
June 17, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/06/17/3100974/0/en/processa-pharmaceuticals-announces-pricing-of-7-million-public-offering.html
Processa Pharmaceuticals Enters Exclusive Licensing Agreement with Intact Therapeutics for PCS12852, Potential Treatment for Gastroparesis
June 17, 2025  |  quiverquant.comQ
Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate
June 17, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/06/17/3100689/0/en/processa-pharmaceuticals-signs-binding-term-sheet-granting-intact-therapeutics-exclusive-option-to-license-phase-2-gastroparesis-drug-candidate.html
Processa Pharmaceuticals to Showcase Next Generation Cancer Therapies at 2025 BIO International Convention
June 15, 2025  |  nasdaq.comhttps://www.nasdaq.com/articles/processa-pharmaceuticals-showcase-next-generation-cancer-therapies-2025-bio-international
Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025
June 13, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/06/13/3098971/0/en/processa-pharmaceuticals-to-engage-potential-partners-and-investors-at-bio-international-convention-2025.html
Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting
May 30, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/05/30/3091075/0/en/processa-pharmaceuticals-announces-presentation-and-publication-of-three-abstracts-at-2025-asco-annual-meeting.html
Processa Pharmaceuticals’ Dr. David Young to Present at World Orphan Drug Congress USA 2025
April 15, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/processa-pharmaceuticals-dr-david-young-to-present-at-world-orphan-drug-congress-usa-2025-1034584299
Processa Pharmaceuticals' Dr. David Young to Present at World Orphan Drug Congress USA 2025
April 15, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/04/15/3061670/0/en/processa-pharmaceuticals-dr-david-young-to-present-at-world-orphan-drug-congress-usa-2025.html
Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference
March 18, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/03/18/3044510/0/en/processa-pharmaceuticals-to-present-at-the-medinvest-biotech-and-pharma-investor-conference.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Marker Therapeutics stock logo

Marker Therapeutics NASDAQ:MRKR

$1.15 -0.02 (-1.37%)
As of 01:59 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

Heatwurx stock logo

Heatwurx NASDAQ:PCSA

$1.90 -0.06 (-3.15%)
As of 01:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas